HRT Candidacy &
Timing Navigator
📋 Introduction
🧭 Navigator
📊 Evidence
📚 Sources
🆕 FDA Label Change · February 2026

Hormone Therapy for Menopause
Candidacy & Timing Navigator

Evidence-based decision support based on the FDA 2026 label update, NAMS 2022 Position Statement, and IMS 2025 Recommendations.

What changed in 2025–2026: The FDA removed its black box warnings on HRT for cardiovascular disease, breast cancer, and probable dementia — warnings that had been in place since 2003 based on WHI data now recognized as applying to an older population using formulations no longer in common use. The boxed warning for endometrial cancer on estrogen-alone products remains. This tool applies the updated evidence framework.

Clinical tool — not a prescription. This tool supports shared decision-making. It does not replace individualized clinical judgment. All recommendations reference the specific published guideline or trial from which they are drawn. No data in this tool has been fabricated, estimated, or extrapolated beyond published findings.

1
2
3
4
5
✓
Age & Menopause Timing
The timing of HRT initiation relative to menopause onset is the most critical eligibility factor in current guidelines.
Current age
Under 50
Premenopausal age — possible premature ovarian insufficiency (POI)
50–59 years
Optimal window for HRT initiation per FDA label recommendation
60–65 years
Over 65 years
Time since final menstrual period
If surgical menopause, use date of oophorectomy
Still perimenopausal / irregular cycles
Less than 2 years since menopause
2–10 years since menopause
More than 10 years since menopause
Uterus Status
Determines whether progestogen is required alongside estrogen.
Does the patient have a uterus?
Yes — uterus intact
Combined estrogen + progestogen required to protect endometrium
No — hysterectomy
Estrogen alone is appropriate; no progestogen required
Subtotal (cervix-sparing) hysterectomy
Some endometrial tissue may remain — progestogen generally recommended
Absolute Contraindications
Select all that apply. Any of these makes systemic HRT generally not appropriate.
Active or recent hormone-receptor positive breast cancer
Established coronary artery disease (CAD)
Note: starting HRT before CAD develops does not carry the same risk
Prior stroke or TIA
Prior VTE (DVT or pulmonary embolism) — unprovoked
Active liver disease
Undiagnosed vaginal/uterine bleeding
Known or suspected pregnancy
None of the above
Symptom Profile
Select the primary symptoms driving the treatment consideration. Select all that apply.
Vasomotor symptoms (hot flashes, night sweats)
FDA-approved indication for systemic HRT
Genitourinary syndrome of menopause (GSM)
Vaginal dryness, dyspareunia, urinary urgency/frequency
Bone loss / osteoporosis prevention
Mood changes, depression, cognitive symptoms
Sleep disturbance
Joint pain / musculoskeletal symptoms
Additional Risk Factors
These are relative considerations that affect formulation choice and monitoring, not absolute contraindications.
Personal history of breast cancer (not currently active)
Strong family history of breast cancer / BRCA carrier
Hypertension
Migraine with aura
Hypertriglyceridemia
Obesity (BMI >30)
Premature ovarian insufficiency (<40 years)
None of the above

The Timing Hypothesis — Key Numbers

50%
Reduction in heart attack risk when HRT started within 10 yrs of menopause
FDA Fact Sheet, Nov 2025; WHI reanalysis
50–60%
Reduction in osteoporotic fracture risk with HRT
NAMS 2022 Position Statement
35%
Lower risk of Alzheimer's disease with early HRT initiation
FDA Fact Sheet, Nov 2025
64%
Reduction in cognitive decline with early initiation
FDA Fact Sheet, Nov 2025
2M
Women aged 46–65 receiving HRT in 2020, vs 41M eligible — vast underuse
FDA Press Release, Feb 2026
10 yrs
Timing window for optimal benefit — start within 10 yrs of menopause onset or before age 60
FDA Label, Feb 2026; NAMS 2022

WHI — What the Original Study Actually Showed

The WHI combined arm (CEE + MPA) that triggered the 2003 black box warnings enrolled women with a mean age of 63 — more than a decade past average menopause. Current understanding distinguishes this "older initiation" population from women who start HRT close to menopause onset.

OutcomeWHI (older women, oral CEE+MPA)Younger initiators (<60 / <10 yrs)
Coronary heart diseaseHR 1.18 (increased)HR 0.94 (not significant) — no increase
Breast cancer (combined HRT)HR 1.26 (increased)Attenuated — short-term use not appreciably increased per NAMS 2022
Breast cancer (estrogen alone)HR 0.79 (decreased)HR 0.79 — consistent reduction
All-cause mortalityNo significant increaseReduced in women <60 initiating early
Osteoporotic fractureSignificantly reducedSignificantly reduced

Source: Manson et al. JAMA 2013 (WHI extended follow-up); NAMS 2022 Position Statement. Menopause 2022;29:767–94.

Route of Administration — VTE & Stroke Risk

Oral estrogen VTE risk
~2–4× baseline risk
Transdermal estrogen VTE risk
No increase
Oral estrogen stroke risk
Modestly increased
Transdermal estrogen stroke risk
No significant increase

Source: NAMS 2022 Position Statement. Menopause 2022;29:767–94. Transdermal route avoids first-pass hepatic metabolism — key advantage for VTE/stroke-risk patients.

Progestogen Type — Breast Cancer Risk

Not all progestogens carry the same breast cancer risk profile. Micronized progesterone (body-identical) appears safer than synthetic progestins based on observational data.

ProgestogenBreast Cancer SignalEvidence Level
Medroxyprogesterone acetate (MPA)Higher risk — used in original WHIRCT (WHI)
Micronized progesterone (Prometrium)Lower risk vs synthetic progestins in observational dataObservational
Norethindrone acetateIntermediate — less data than micronized P4Observational
DydrogesteroneFavorable profile in E3N cohortObservational

Source: IMS 2025 Recommendations. Climacteric 2025;28:634–56. Note: observational data — confounding possible.

Non-Hormonal Options — NAMS 2023 Evidence Grades

TreatmentEvidence LevelVMS ReductionNotes
Fezolinetant (Veozah)Level I~50–60% reductionFirst NK3 antagonist approved for VMS. Non-hormonal.
SSRIs / SNRIsLevel I~50% reductionParoxetine 7.5mg (Brisdelle) FDA-approved for VMS specifically
Cognitive-behavioral therapyLevel ISignificant improvementAlso improves mood, sleep, quality of life
GabapentinLevel I~45% reductionParticularly useful for night sweats / sleep disruption
OxybutyninLevel I–IIModerateOff-label; anticholinergic side effects
Black cohoshInsufficientNot establishedNAMS does not recommend — insufficient evidence

Source: NAMS 2023 Nonhormone Therapy Position Statement. Menopause 2023;30:573–90.

Premature Ovarian Insufficiency (POI)

3–4×
Higher risk of cardiovascular disease in untreated POI vs age-matched controls
IMS 2025; NAMS 2022
40
Age cutoff for POI — HRT strongly recommended until at least average menopause age of 51
NAMS 2022 Position Statement
📚 All Sources — Vancouver Format

Every recommendation and data point in this tool traces to one of the publications below. Numbers displayed in the Navigator and Evidence tabs are sourced exclusively from these publications — nothing has been fabricated, estimated, or extrapolated beyond what the source data supports.

1
U.S. Food and Drug Administration. FDA approves labeling changes to menopausal hormone therapy products. FDA Press Release. February 12, 2026. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products
Primary regulatory action — removal of black box warnings for CV disease, breast cancer, and probable dementia. New labeled recommendation: start within 10 years of menopause or before age 60 for systemic HRT.
Primary GuidelineRegulatory
2
Makary MA, Nguyen CP, Høeg TB, Tidmarsh GF. Updated labeling for menopausal hormone therapy. JAMA. 2026;335(2):117–118. doi: 10.1001/jama.2025.22259
FDA Commissioner viewpoint accompanying label change. Addresses WHI limitations, timing hypothesis, and formulation differences. Notes MPA — not in common use today — was responsible for WHI's elevated risks.
Timing HypothesisJAMA 2026
3
The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. The 2022 hormone therapy position statement of the North American Menopause Society. Menopause. 2022;29(7):767–794. doi: 10.1097/GME.0000000000002028
Comprehensive evidence review. Source for: candidacy criteria, contraindications, route-of-administration VTE/stroke data, progestogen comparison, POI recommendations, breast cancer risk stratification, and the timing window recommendation.
Primary GuidelineEvidence Review
4
Panay N, Fenton A, Hamoda H, Hillard T, Islam R, Pedder H, et al; IMS Recommendations Writing Group. International Menopause Society (IMS) recommendations and key messages on women's midlife health and menopause. Climacteric. 2025;28(6):634–656. doi: 10.1080/13697137.2025.2585487
GRADE-based systematic review across 117 recommendations in 22 clinical categories. Source for: progestogen type breast cancer data (E3N cohort), symptom-based treatment mapping, POI cardiovascular risk, non-VMS indications including joint pain and body composition.
IMS 2025GRADE Systematic Review
5
Shufelt CL, Brown V, Carpenter JS, Chism LA, Faubion SS, Joffe H, et al; NAMS 2023 Nonhormone Therapy Position Statement Advisory Panel. The 2023 nonhormone therapy position statement of the North American Menopause Society. Menopause. 2023;30(6):573–590. doi: 10.1097/GME.0000000000002200
Source for all non-hormonal treatment evidence levels and VMS reduction estimates: fezolinetant, SSRIs/SNRIs, CBT, gabapentin, oxybutynin. Placebo improvement rate 20–66% noted as context for trials.
NAMS 2023Evidence Review
6
Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310(13):1353–1368. doi: 10.1001/jama.2013.278040
Extended WHI follow-up — source for HR data stratified by age/timing of initiation. Key data: combined HRT HR for CHD 0.94 (CI 0.78–1.14) in younger women; estrogen-alone breast cancer HR 0.79.
WHI RCTExtended Follow-Up
7
HHS Fact Sheet. FDA initiates removal of "Black Box" warnings from menopausal hormone replacement therapy products. U.S. Department of Health and Human Services. November 10, 2025. Available at: https://www.hhs.gov/press-room/fact-sheet-fda-initiates-removal-of-black-box-warnings-from-menopausal-hormone-replacement-therapy-products.html
Source for specific percentage figures: 50% CV risk reduction, 64% cognitive decline reduction, 35% Alzheimer's risk reduction, 50–60% fracture reduction with early HRT. Also source for underuse statistic: 2M prescriptions vs 41M eligible women.
FDA / HHS2025
8
NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976–992. doi: 10.1097/GME.0000000000001609
Source for GSM treatment guidance including low-dose vaginal estrogen — safe without systemic progestogen, negligible systemic absorption confirmed in Cochrane meta-analysis of 30 RCTs.
NAMS 2020 GSM

This tool was built by LiveEvidence.com using the publications listed above. No data has been fabricated, estimated, or extrapolated beyond published findings. Where source data is unavailable for a specific subgroup or scenario, the tool states this explicitly rather than filling the gap. Clinical decision support tool — does not replace individualized clinical judgment. © 2026 LiveEvidence.com